Chengdu huasun technology group Inc. , LTD. cancelled the acquisition of Sichuan Bohaoda Biotechnology Co., Ltd. from Sichuan Yuanhong Biotechnology Co., Ltd. and Chengdu Bohaoda Biotechnology Co., Ltd.
July 10, 2024
Share
Chengdu huasun technology group Inc. , LTD. (SZSE:000790) agreed to acquire Sichuan Bohaoda Biotechnology Co., Ltd. from Sichuan Yuanhong Biotechnology Co., Ltd. and Chengdu Bohaoda Biotechnology Co., Ltd. for CNY 1 billion on June 19, 2023. Chengdu huasun technology group will pay the consideration by issuing new shares at CNY 3.9 per share. Sichuan Bohaoda Biotechnology reported total assets of CNY 299.1127 million, net assets of CNY 196.1454 million, operating revenue of CNY 131.2527 million and net profit of CNY 46.7881 million till December 31, 2022. The transaction is subject to approval from sellers, shareholders of Chengdu huasun technology group, approval from Shenzhen Stock Exchange and CSRC. The transaction has been approved by Directorate meeting of Chengdu huasun technology group. CSC Financial Co., Ltd. acted as financial advisor, Sichuan Huaxin(Group) Certified Public Accountants Co.,Ltd. acted as accountant and Grandway Law Offices acted as legal advisor to Chengdu huasun technology group Inc. , LTD.
Chengdu huasun technology group Inc. , LTD. (SZSE:000790) cancelled the acquisition of Sichuan Bohaoda Biotechnology Co., Ltd. from Sichuan Yuanhong Biotechnology Co., Ltd. and Chengdu Bohaoda Biotechnology Co., Ltd. on July 10, 2024.
Chengdu Huasun Technology Group Co Ltd, formerly Chengdu Taihe Health Technology Group Inc., Ltd., is principally engaged in manufacture and distribution of Chinese medicines and Western medicines, fabrication and installation services of steel structures, as well as production and sale of bio-engineering products. The Company primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The Company operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
Chengdu huasun technology group Inc. , LTD. cancelled the acquisition of Sichuan Bohaoda Biotechnology Co., Ltd. from Sichuan Yuanhong Biotechnology Co., Ltd. and Chengdu Bohaoda Biotechnology Co., Ltd.